Showing 6421-6430 of 7509 results for "".
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Cynosure Launches TempSure Vitalia for Feminine Wellnesshttps://practicaldermatology.com/news/cynosure-launches-tempsure-vitalia-for-feminine-wellness/2457696/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to internal
- Fourth Generation Retinoid Shows Promise in Acne Trialshttps://practicaldermatology.com/news/fourth-generation-retinoid-shows-promise-in-acne-trials/2457699/New research reveals that trifarotene, a fourth-generation retinoid with potent and selective activity against only one particular retinoic acid receptor, may have an improved efficacy and safety profile compared with less selective r
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- Alana Sine is New CFO at Merz North Americahttps://practicaldermatology.com/news/alan-sine-is-new-cfo-at-merz-north-america/2457719/Merz North America has appointed Alana Sine as Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing finan
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve